The Nature of the Drug: Invokana is a drug prescribed to treat Type 2 (adult onset) diabetes. It was developed by the Japanese company Mitsubishi Tanabe Pharma, and is marketed in the United States by Janssen, a division of Johnson & Johnson. Invokana belongs to the class of drugs called subtype 2 sodium-glucose transport (SLGT-2) inhibitors, which work by encouraging the kidneys to release more sugar into the urine as a way of managing blood-sugar level.
